Krsnaa Diagnostics Limited receives income tax appellate orders for multiple assessment years.
Krsnaa Diagnostics received income tax appellate orders for AYs 2017-24. The aggregate disputed demand is ₹62.69 crore. Appeals for AYs 2017-20 were dismissed, while AYs 2021-24 were partly allowed. The company plans to appeal further at the ITAT.
The aggregate disputed demand is significant at over ₹62 crore. Although the company believes it has grounds for appeal and expects relief, the ongoing litigation and potential financial implications warrant a medium impact assessment.
The company has received adverse orders at the first appellate level, but it disputes the demands and plans to appeal further. While some appeals were partly allowed, others were dismissed. The outcome of further proceedings is uncertain, making the sentiment neutral.
Krsnaa Diagnostics Limited has received orders from the Commissioner of Income Tax (Appeals), Pune, concerning Assessment Years 2017-18 through 2023-24. These orders represent the outcome at the first appellate level in ongoing income-tax proceedings.
The company disputes the underlying tax demands and intends to file further appeals before the Hon’ble Income Tax Appellate Tribunal (ITAT). The orders were passed on various dates in August and September 2026. For Assessment Year 2017-18, the disputed demand was ₹2,08,24,611, with the appeal dismissed. Similarly, appeals for AY 2018-19 (₹4,03,75,969), AY 2019-20 (₹7,26,78,730), and AY 2020-21 (₹8,69,02,910) were also dismissed.
Appeals for AY 2021-22 (₹14,20,42,704), AY 2022-23 (₹19,63,30,624, with a subsequent revised balance payable of ₹31,73,28,734), and AY 2023-24 (₹6,77,61,887) were partly allowed. The aggregate disputed demand reflected in these orders amounts to ₹62,69,17,435. The company, in consultation with external tax experts, believes it has strong grounds for appeal and expects substantial relief.
These matters are under further statutory appellate proceedings and do not impact the company's ongoing operations. Financial and accounting implications will be assessed and accounted for according to applicable standards.
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.